- Home
- KUKE vs FBRX Comparison
KUKE vs FBRX Comparison
Compare KUKE & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- FBRX
- Stock Information
- Founded
- KUKE 2002
- FBRX N/A
- Country
- KUKE China
- FBRX United States
- Employees
- KUKE N/A
- FBRX N/A
- Industry
- KUKE Other Consumer Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- FBRX Health Care
- Exchange
- KUKE Nasdaq
- FBRX Nasdaq
- Market Cap
- KUKE 86.8M
- FBRX 84.0M
- IPO Year
- KUKE 2021
- FBRX N/A
- Fundamental
- Price
- KUKE $3.07
- FBRX $12.75
- Analyst Decision
- KUKE
- FBRX Strong Buy
- Analyst Count
- KUKE 0
- FBRX 2
- Target Price
- KUKE N/A
- FBRX $61.00
- AVG Volume (30 Days)
- KUKE 8.9K
- FBRX 167.7K
- Earning Date
- KUKE 07-31-2025
- FBRX 08-13-2025
- Dividend Yield
- KUKE N/A
- FBRX N/A
- EPS Growth
- KUKE N/A
- FBRX N/A
- EPS
- KUKE N/A
- FBRX N/A
- Revenue
- KUKE $9,442,397.00
- FBRX N/A
- Revenue This Year
- KUKE N/A
- FBRX N/A
- Revenue Next Year
- KUKE N/A
- FBRX N/A
- P/E Ratio
- KUKE N/A
- FBRX N/A
- Revenue Growth
- KUKE N/A
- FBRX N/A
- 52 Week Low
- KUKE $1.45
- FBRX $4.11
- 52 Week High
- KUKE $17.50
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- KUKE 44.72
- FBRX 55.63
- Support Level
- KUKE $2.95
- FBRX $10.15
- Resistance Level
- KUKE $3.03
- FBRX $13.48
- Average True Range (ATR)
- KUKE 0.11
- FBRX 1.95
- MACD
- KUKE 0.04
- FBRX -0.18
- Stochastic Oscillator
- KUKE 53.54
- FBRX 27.45
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).